PositiveID gains momentum after increased focus on biothreat detection

William Caragol, the chairman and CEO of PositiveID, said on Monday that the heightened focus on the need for biothreat detection by the federal government is helping the company gain momentum.

During an interview with Investorideas.com, Caragol discussed the recent partnerships PositiveID forged with commercial and federal government organizations. The contracts include a $841,000 contract with the DoD to test PositiveIDs Microfluidic Bio-agent Autonomous Networked Detector (M-BAND) and a Space Act Agreement with NASA's Ames Research Center.

"When an organization with the respect and recognition that NASA has earned wants to work with you and further the development of your technology to see how it may help them in their specific endeavors, it is significant," Caragol said. "As we pursue opportunities with other government and commercial entities, having a group like NASA standing by our side makes people take notice. Having third-party support, especially when it comes from a group of world-class scientists, is very important for a small company like PositiveID."

When asked if the momentum and traction PositiveID gained from high profile institutions and agencies is the reflection of a renewed sense of urgency to address biothreats, Caragol said the world has seen the danger posed by WMDs.

"Unfortunately, we've witnessed global events that underscore the danger posed by biological weapons of mass destruction," Caragol said. "That said, there definitely is a heightened focus on the need for bio-threat detection, and a pick-up in government procurements for these technologies. At the same time, however, it's not simply a matter of being in the right place at the right time. We have worked diligently to create the necessary partnerships to successfully capture the opportunities ahead of us."

PositiveID develops microfluidic systems for the automated preparation and performance of biological assays to detect biological threats and analyze biological samples.